Lipocine Q2 2024 GAAP EPS $(0.56) Beats $(0.78) Estimate, Sales $89.565K Miss $290.000K Estimate
Portfolio Pulse from Benzinga Newsdesk
Lipocine (NASDAQ:LPCN) reported Q2 2024 GAAP EPS of $(0.56), beating the $(0.78) estimate, but sales of $89.565K missed the $290.000K estimate.
August 08, 2024 | 10:30 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Lipocine's Q2 2024 GAAP EPS of $(0.56) beat estimates by 28.21%, but sales of $89.565K missed estimates by 69.12%.
While Lipocine's EPS beat expectations significantly, the substantial miss in sales could offset positive sentiment. Investors may have mixed reactions, leading to neutral short-term price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100